Hepatitis B vaccine booster dose: Low-dose recombinant hepatitis B vaccines as a booster dose

American Journal of Infection Control

Volumn 25, Issue 3, 1997, Pages 215-222

  Bryan, Joe P ^a   MacArthy, Philip ^b   Rudock, A I ^a   Fogarty, John P ^a   Dowd, Hugh ^a   Legters, Llewellyn J ^a   Perine, Peter L ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; ANTIGEN DETECTION; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FOLLOW UP; GEOMETRY; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; VACCINATION;

EID: 0030950720     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-6553(97)90007-9     Document Type: Article

References (26)

1. Nommensen F, Go S, MacLaren D. Half-life of HBs antibody after hepatitis B vaccination: an aid to time of booster vaccination. Lancet 1989;2:847-9.
2. Coursaget P, Yvonnet B, Gilks W, et al. Scheduling of revaccination against hepatitis B virus. Lancet 1991;337:1180-3.
3. Bryan J, Sjogren M, Perine P, Legters L. Low-dose intradermal and intramuscular hepatitis B vaccination. Clin Infect Dis 1992;14:697-707.
4. Tilzey A, Palmer S, Banatvala J, Vines S, Gilks W. Hepatitis B vaccine boosting among young healthy adults. Lancet 1994;344:1438-9.
5. Petersen K, Parkinson A, McMahon B, et al. Antibody persistence and response to boosters nine years after infant vaccination with hepatitis B vaccine. Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: American Society for Microbiology; 1995. p. H70.
6. Hadler H, Francis D, Maynard J, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-14.
7. Hadler S, Coleman P, O'Malley P, Judson F, Altman N. Evaluation of long term protection by hepatitis B vaccine in homosexual men followed for 7-9 years. In: Hollinger F, Lemon S, Margolis H, editors. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease. Baltimore: Williams and Wilkins; 1991. p. 766.
8. Pegues D, Woodruff B, Lambert S, Tant M, Woernle C. Immune response to Intramuscular revaccination after primary intradermal vaccination against hepatitis B. Clin Infect Dis 1995;20:335.
9. Bryan J, Sjogren M, Iqbal M, et al. Comparative trial of low-dose, intradermal, recombinant- and plasma-derived hepatitis B vaccination. J Infect Dis 1990;162:789.
10. Wood R, MacDonald K, White K, Hedberg C, Hanson M, Osterholm M. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:2935.
11. Roome A, Walsh S, Cartter M, Hadler J. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931.
12. Bryan J, Sjogren M, MacArthy P, Cox E, Legters L, Perine P. Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose. Vaccine 1991;10:33.
13. Davidson M, Krugman S. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: Immunogenicity and effect of a booster dose. J Infect 1986; 13(suppl A):31.
14. Dupont W, Plummer W. Power and sample size calculations: a review and computer program. Controlled Clinical Trials 1990;11:116.
15. Horowitz M, Ershler W, McKinney W, Battiola R. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med 1988;108:185.
16. McKinney W, Russler S, Horowitz M, Battiola R, Lee M. Duration of response to intramuscular versus low dose intradermal hepatitis B booster immunization. Infect Control Hosp Epidemiol 1991;12:226.
17. Thompson S, Darlington R, Tallent D, Forsyth J. Booster doses of hepatitis B vaccine: responses to low-dose inoculations. Med J Aust 1993;158:375.
18. Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991;40(No. RR-13):11.
19. Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last? Lancet 1984;2:458.
20. Gesemann M, Scheiermann N. Quantification of hepatitis B vaccine induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995;13:443.
21. Wainwright B, McMahon B, Bulkow L, Parkinson A, Harpster A, Hadler S. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population - preliminary results of an 8-year study. In: Hollinger F, Lemon S, Margolis H, editors. Viral hepatitis and liver disease: proceeding of the 1990 International Symposium on Viral Hepatitis and Liver Disease: contemporary issues and future prospects. Baltimore: Williams and Wilkins; 1991. p. 762.
22. Andre F, Safary A. Clinical Experience with a yeast-derived hepatitis B vaccine. In: Zuckerman A, editors. Viral hepatitis and liver disease. New York: Alan R Liss; 1988. p. 1025.
23. de Knegt R, Grosheide P, Heijtink R, Schalm S. Low dose hepatitis B vaccination with recombinant vaccines in medical students. In: Hollinger F, Lemon S, Margolis H, editors. Viral hepatitis and liver disease. Baltimore: William & Wilkins; 1991. p. 741.
24. Bryan J, Craig P, MacArthy P, et al. Randomized comparison of 5 and 10 μg doses of two recombinant hepatitis B vaccines. Vaccine 1995;13:978.
25. Thompson S, Darlington R, Tallent D, Robins-Browne R, Forsythe J. Effectiveness of low-dose intradermal hepatitis B vaccination: five years' experience of primary vaccination. Med J Aust 1993;158:372.
26. McMaster K, Roper J, Carter J. Intradermal hepatitis B vaccination in a 300-bed primary care hospital: experience with a recombinant vaccine in a four-dose schedule. AJIC Am J Infect Control 1993;21:283